|
October 2, 2006 |
|
Launch of Contract Research based on Agreement with JST |
|
|
|
We hereby announce that TRANS GENIC INC. (hereinafter referred to as q・eq・ started to conduct a contract research for a funded program of q④ollaborative Development of Innovation Seeds, Potentiality Verification Stageq・(hereinafter referred to as q㏄he programq・ committed by the Japan Science and Technology Agency (hereinafter referred to as q⑪STq・. |
|
We concluded a contract research agreement with JST on October 1, 2006 regarding q㌧evelopment of next-generation gallbladder tumor markers for early detection of carcinomaq・ a subject selected for the program (see JSTq・ press release on September 20, 2006), and started to act as a q㎏eeds verification producerq・accordingly. The program of JST aims to connect seeds candidate
that is found out through industry's viewpoint from basic research
in universities, national and other public research institutes
to innovation creation. We have focused on an achievement regarding specific
gallbladder cancer diagnosis, made by Dr. Nobuo Sakaguchi, professor
of Faculty of Medical and Pharmaceutical Sciences, Kumamoto University,
as a new seeds candidate. As a seeds verification producer, we
will carry out research and development with Kumamoto University
to
put it into practical use as a clinical diagnostic reagent. The
seeds candidate has a We and Dr. Sakaguchi have successfully commercialized q㍗igh-affinity antibody producing technology using GANP mouse (international patent publication number: WO2004/040971)q・ Once feasibility of the seeds candidate is verified through the contract research, we will cooperatively conduct research and development to commercialize it. The potential influences of this matter on our business
performance for the fiscal term ending March, 2007 are as yet immaterial. Please see a list of subjects adopted for the 2nd q④ollaborative
Development of Innovation Seeds, Potentiality Verification Stageq・
in FY 2006.
|
 |
 |